

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Amendment (No. 7) Determination 2023

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 7 December 2023

Nikolai Tsyganov Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care



Contents

1	Name	1
2	Commencement	1
3	Authority	1
4	Schedules	1

Schedule 1—Amendments

2

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Determination 2021



1 Name

- (1) This instrument is the National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages)
 Amendment (No. 7) Determination 2023.
- (2) This instrument may also be cited as PB 126 of 2023.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information					
Column 1	Column 2	Column 3			
Provisions	Commencement	Date/Details			
1. The whole of this instrument	11 December 2023	11 December 2023			

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the *National Health Act* 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Determination 2021

1 Subsection 5(8)

Repeal the table, substitute:

Item	Column 1	Column 2
	Prescribed pharmaceutical benefit	Substitute pharmaceutical benefit
1	Listed drug: Insulin degludec with insulin aspart Form: Injections, pre-filled pen, 70 units-30	Listed drug: Insulin degludec with insulin aspart Form: Injections, cartridges, 70 units-30 units per mL, 3 mL, 5
	units per mL, 3 mL, 5	Manner of administration: Injection
	Manner of administration: Injection	Brand: Ryzodeg Penfill
	Brand: Ryzodeg Flextouch	
2	Listed drug: Cefalexin	Listed drug: Cefalexin
	Form: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL	Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL
	Manner of administration: Oral	Manner of administration: Oral
	Brand: any of the following:	Brands: any of the following:
	(a) Cefalexin Sandoz	(a) Cefalexin Sandoz
	(b) Ibilex 125	(b) Ibilex 250
	(c) Keflex	(c) Keflex
3	Listed drug: Cefalexin	Listed drug: Cefalexin
	Form: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL	Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL (s19A)
	Manner of administration: Oral	Manner of administration: Oral
	Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 125 (c) Keflex	Brand: Keforal (s19A)
4	Listed drug: Cefalexin	Listed drug: Cefalexin
	Form: Granules for oral suspension 125 mg	Form: Capsule 250 mg (as monohydrate)
	(as monohydrate) per 5 mL, 100 mL	Manner of administration: Oral
	Manner of administration: Oral	Brands: any of the following:
	Brand: any of the following:	(a) APO-Cephalexin
	(a) Cefalexin Sandoz	(b) Ibilex 250
	(b) Ibilex 125	(c) Keflex
	(c) Keflex	
5	Listed drug: Cefalexin	Listed drug: Cefalexin
	Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL	Form: Granules for oral suspension 125 mg (as monohydrate) per 5 mL, 100 mL

² National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescriptions during Shortages) Amendment (No.7) Determination 2023

Mannar of administration, Oral	Mannar of administration: Oral
	Manner of administration: Oral
	Brands: any of the following:
	(a) Cefalexin Sandoz(b) Ibilex 125
` '	(c) Keflex
	Listed drug: Cefalexin
Form: Granules for oral suspension 250 mg	Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL (s19A)
Manner of administration: Oral	Manner of administration: Oral
Brand: any of the following:	(a) Brand: Keforal (s19A)
(a) Cefalexin Sandoz	
(b) Ibilex 250	
(c) Keflex	
Listed drug: Cefalexin	Listed drug: Cefalexin
Form: Granules for oral suspension 250 mg	Form: Capsule 250 mg (as monohydrate)
(as monohydrate) per 5 mL, 100 mL	Manner of administration: Oral
Manner of administration: Oral	Brand: any of the following:
Brand: any of the following:	(a) APO-Cephalexin
(a) Cefalexin Sandoz	(b) Ibilex 250
` '	(c) Keflex
(c) Keflex	
Listed drug: Vigabatrin	Listed drug: Vigabatrin
Form: Tablet 500 mg	Form: Oral powder, sachet 500 mg
Manner of administration: Oral	Manner of administration: Oral
Brand: Sabril	Brand: Sabril
Listed drug: Fluoxetine	Listed drug: Fluoxetine
Form: Toblet dispersible 20 mg (es	Form: Capsule 20 mg (as hydrochloride)
Form. Tablet, dispersible, 20 mg (as	1 orm. Capsule 20 mg (as nyaroemoriae)
hydrochloride)	Manner of administration: Oral
- · · · · · · · · · · · · · · · · · · ·	
hydrochloride)	Manner of administration: Oral Brand: any of the following:
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine (d) FLUOTEX
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine (d) FLUOTEX (e) Fluoxetine APOTEX
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine (d) FLUOTEX (e) Fluoxetine APOTEX (f) Fluoxetine Sandoz
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine (d) FLUOTEX (e) Fluoxetine APOTEX (f) Fluoxetine Sandoz (g) Fluoxetine generichealth
hydrochloride) Manner of administration: Oral	Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine (d) FLUOTEX (e) Fluoxetine APOTEX (f) Fluoxetine Sandoz
	(as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 250 (c) Keflex Listed drug: Cefalexin Form: Granules for oral suspension 250 mg (as monohydrate) per 5 mL, 100 mL Manner of administration: Oral Brand: any of the following: (a) Cefalexin Sandoz (b) Ibilex 250 (c) Keflex Listed drug: Vigabatrin Form: Tablet 500 mg Manner of administration: Oral Brand: Sabril